Precipitated by the COVID-19 pandemic and the resultant increased use of personal protective equipment (PPE) in citizens who are not health-care workers, Dr Giovanni Damiani (University of Milan, Italy) and his team conducted a multi-centre, observational study consisting of 2 phases [1]. The first phase documented the prevalence of different mask types for 5 months, and the second phase documented the effect of masks on acne vulgaris and rosacea for 3 months.
Masks disrupt the microenvironment of the face, changing both the microbiome and the mycobiome. Wearing a mask also causes mechanical friction. The combination of these factors can cause aggravation of pre-existing acne vulgaris and rosacea.
Reporting on 15 patients (10 with acne vulgaris and 5 with rosacea) and using the Global Acne Grading System (GAGS), Dr Damiani and his team noted an increased severity of acne vulgaris and rosacea complaints, particularly in the cheeks, nose, and chin regions. The effect was more marked in cases in which non-surgical masks were used. Dermatoses complaints tripled after quarantine, after which mask usage increased. All patients were wearing a mask for a minimum of 6 hours per day.
The researchers recommend that mask regulation become mandatory to decrease facial dermatoses and that ad-hoc therapies be studied because mask acne (“maskne”) and mask rosacea are more resistant to therapies.
- Damiani G, et al. The impact of personal protective equipment on acne vulgaris and rosacea during the COVID-19 pandemics. FC01.07, EADV Virtual Congres, 29-31 October 2020.
Posted on
Previous Article
« ECNP 2020 Highlights Podcast Next Article
Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria »
« ECNP 2020 Highlights Podcast Next Article
Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria »
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com